tbuckley/cabot-search huggingface dataset:
PRIOR CARDIOVASCULAR DISEASE, DIABETES AND CHRONIC KIDNEY DISEASE AND THE RISK OF RECURRENT CARDIOVASCULAR DISEASE FOLLOWING A MYOCARDIAL INFARCTION
Authors: Demetria Hubbard, Lisandro Colantonio, Robert S. Rosenson, Todd Brown, Elizabeth Jackson, Lei Huang, Kate Orroth, Stephanie Reading, Mark Woodward, Vera Bittner, Orlando Gutierrez, Monika Safford, Michael E. Farkouh, Paul Muntner
Journal: Journal of the American College of Cardiology (2020)
Remarkable response of adult-onset ganglioneuroblastoma in the advanced stage to unrelated cord blood transplantation: Case report
Authors: T. Takahashi, T. Morii, I. Amano, H. Tanaka, T. Tojo, S. Taniguchi, H. Kimura
Journal: Journal of Clinical Oncology (2006)

11524 Background: Adult-onset ganglioneuroblastoma (GNB) is a rare disease that carries the gravest prognosis. In this case report, we discuss a case of adult-onset GNB in the advanced stage which has responded favorably to unrelated cord blood transplantation (UCBT). Methods: The patient was a 22-year-old male. Posterior mediastinal tumor was excised and a diagnosis of GNB was made. The severity of GNB was classified as stage IV because bone metastasis affected the entire body. Three courses of combination chemotherapy using cisplatin (CDDP), cyclophosphamide (CY), vincristine sulfate (VCR) and pirarubicin hydrochloride-adriamycin (THP-ADR) turned out to be ineffective. Local radiation therapy to control the tumor metastasis to the right great wing of the sphenoid bone resulted in augmentation of the tumorous lesion. Then, bone marrow destructive pretreatment consisting of anticancer therapy [etoposide (VP-16) and thiotepa] and total body irradiation (TBI, 12Gy) was followed by UCBT. Cyclosporin and mycophenolate mofetil were administered to prevent graft versus host disease (GVHD). Results: The blood type compatible two-loci HLA mismatch transplant had 3.2x107 nucleated cells/kg. After the cord blood transplantation, the patient suffered complications such as acute GVHD (grade III), veno-occlusive disease (VOD) and viral hemorrhagic cystitis. Neuron-specific enolase (NSE), a GNB tumor marker, gradually decreased from 220 ng/ml to the normal level. The bone metastatic tumors were reduced in a stepwise manner. Fluorodeoxyglucose-positron-emission tomography (FDG-PET) scan demonstrated complete disappearance of abnormal accumulation. Three hundred days have passed since the unrelated cord blood transplantation. The patient is surviving and in the disease-free state. Conclusion: The remarkable response of adult-onset GNB in the advanced stage to UCBT has demonstrated the definite graft versus tumor (GVT) effect of UCBT on GNB. UCBT is regarded as a promising therapeutic intervention in solid tumors that are not associated with blood disorder. No significant financial relationships to disclose.
RADIOLOGIC FINDINGS SUGGESTIVE OF PORTAL HYPERTENSION MAY IDENTIFY PATIENTS AT RISK FOR FONTAN FAILURE
Authors: Faizeen Zafar, Mathias Possner, Andrew T. Trout, Angela Lorts, Joseph J. Palermo, Cassandra Szugye, Jonathan R. Dillman, Gruschen R. Veldtman, Alexander Opotowsky, Adam Lubert, Tarek Alsaied
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND SUBSEQUENT MAJOR ADVERSE CARDIOVASCULAR AND CEREBRAL EVENTS IN PATIENTS UNDERGOING PCI FOR ACS AND NORMAL LEFT VENTRICLE EJECTION FRACTION
Authors: Jiali Wang, Shumei Zhao, Xue-Qiao Zhao, Hui Chen, Hui-Qiang Zhao, Dong-Bao Li, Chun-Yan Guo, Hongwei Li
Journal: Journal of the American College of Cardiology (2020)
CIRCULATING CELLULAR ADHESION MOLECULES IN YOUNG ADULTHOOD AND ADVERSE CARDIAC FUNCTION IN LATER LIFE: THE CARDIA STUDY
Authors: Ravi B. Patel, Laura Colangelo, Alexander P. Reiner, Myron Gross, David R. Jacobs, Joao A.C. Lima, Sanjiv Jayendra Shah, Donald M. Lloyd-Jones
Journal: Journal of the American College of Cardiology (2020)
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors
Authors: Hjalmar Wadström, Andreas Pettersson, Karin E Smedby, Johan Askling
Journal: Annals of the Rheumatic Diseases (2020)

Objectives To examine the risk of incident breast cancer in women with rheumatoid arthritis (RA), and the risk of RA in women with a history of breast cancer, taking antihormonal treatment for breast cancer into account. Methods Using nationwide Swedish registers, women with new-onset RA diagnosed in 2006–2016 were identified and analysed using a cohort and a case–control design. Each patient with RA was matched on age, sex and place of residence to five randomly selected subjects from the general population. Through register linkages, we collected information on breast cancer, breast cancer risk factors (reproductive history and hormone replacement therapy) and socio-economy. The relative risk of breast cancer after RA was assessed using Cox regression, and the relative risk of RA in women with a history of breast cancer was assessed using conditional logistic regression. Results The risk of incident breast cancer in women with RA was reduced and the association was not attenuated by adjustment for breast cancer risk factors (HR=0.80, 95% CI 0.68 to 0.93). The risk of RA in women with a history of breast cancer was similarly reduced (OR=0.87, 95% CI 0.79 to 0.95). Women with breast cancer treated with tamoxifen (OR=0.86, 95% CI 0.62 to 1.20) or aromatase inhibitors (OR=0.97, 95% CI 0.69 to 1.37) did not have an increased risk of RA compared with women with breast cancer treated differently. Conclusions The decreased occurrence of breast cancer in patients with RA is present already before RA diagnosis; these reduced risks are not readily explained by hormonal risk factors. Adjuvant antihormonal therapy for breast cancer does not seem to increase RA risk.
CHARACTERIZING THE PREVALENCE AND ECHOCARDIOGRAPHIC PROFILE OF PATIENTS WITH PARADOXICAL LOW-GRADIENT MITRAL STENOSIS
Authors: Nicholas Ngiam, Nicholas Chew, Ching-Hui Sia, Hui Wen Sim, Benjamin Tan, William Kong, Tiong-Cheng Yeo, Kian Keong Poh
Journal: Journal of the American College of Cardiology (2020)
Validation of the M. D. Anderson symptom inventory (MDASI-BT)
Authors: T. S. Armstrong, T. Mendoza, I. Gning, C. Coco, M. R. Gilbert, C. Cleeland, M. Z. Cohen, L. Eriksen
Journal: Journal of Clinical Oncology (2006)

1546 Background: The occurrence of symptoms has been shown to predict treatment course and survival in a number of solid tumor patients. Primary brain tumor patients are unique in the neurologic symptoms that occur. Currently, no instrument exists that measures both neurologic and cancer-related symptoms. Methods: Patients diagnosed with Primary Brain Tumors (PBT) participated in this study. Data collection tools included a patient completed demographic data sheet, an investigator completed clinician checklist, and the core M.D. Anderson Symptom Inventory to which 18 neurologic symptoms were added (M.D. Anderson Symptom Inventory-Brain Tumor Module, MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients. Results: 201 patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22. Regression analysis showed more than half (56%) of the variability in symptom severity was explained by the 9 remaining brain tumor items. Factor analysis was then performed to determine the underlying constructs being evaluated by the remaining items. The 22 item MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the sets of items comprising the six factors and also the interference scale were .87, .82, .72, .81, .69, .67 and .91 respectively). Test-retest reliability was good in a subset of 19 patients completing the instrument at two points in time. The MDASI-BT was sensitive to disease severity based on Karnofsky performance status (KPS) based on mean symptom severity (1.7 versus 3.8, p &lt; .001) and mean symptom interference (2.2 versus 6.1, p &lt; .001). Conclusions: The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to describe symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management. [Table: see text]
SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY WITH NORMAL RESTING AND STRESS LEFT VENTRICULAR OUTLET TRACT GRADIENT DIAGNOSED WITH INVASIVE PROVOCATIVE TESTING
Authors: Abdul Haseeb, Hamza Hafeez, Sharath Rajagopalan, Mirza Mujadil Ahmad, Raza Mian, Najam Saqib, Muhammad Siddique Pir, Muhammad Bilal, Nicholas Ierovante
Journal: Journal of the American College of Cardiology (2020)
Changing the Course of Cancer Care With Greater Precision
Authors: S. Yousuf Zafar, Hanna K. Sanoff
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
IMAGING EVALUATION FOR MITRAL LEAFLET MORPHOLOGY CORRELATION OF COMPUTED TOMOGRAPHY WITH TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Alan Vainrib, Hasan Jilaihawi, Makoto Nakashima, Sonja Paschke, Joseph Tovar, Cezar Staniloae, Homam Ibrahim, Michael Querijero, Kazuhiro Hisamoto, Larry Latson L, Carlos Gonzalez, Jorge Fuentes, Muhamed Saric, Mathew Williams
Journal: Journal of the American College of Cardiology (2020)
OUTCOMES OF MITRAL VALVE SURGERY DURING AN ACUTE MYOCARDIAL INFARCTION
Authors: Abel E. Moreyra, Harsh Doshi, Yi Yang, Stavros Zinonos, Nora M. Cosgrove, Mingyao Xiao, John B. Kostis, Javier Cabrera, William J. Kostis
Journal: Journal of the American College of Cardiology (2020)
Symptom burden among metastatic cancer patients receiving palliative chemotherapy.
Authors: Herdee Gloriane Cristal Luna, Jose Enrique Montoya, Amherstia Morelos, Jose Roberto Amparo, Leo Marbella, Reynaldo Lesaca, Gloria R. Cristal-Luna
Journal: Journal of Clinical Oncology (2013)

e20696 Background: Cancer-related symptoms are less investigated but frequently reported patient-experienced symptom clusters. In palliative oncology, focus is on recognizing and addressing these symptoms, and giving quality of life. The purpose of this study is to determine the severity of cancer related symptoms among metastatic cancer patients on palliative chemotherapy using the MD Anderson Symptom Inventory (Filipino) [MDASI-F]. Methods: A cross-sectional study among metastatic cancer patients undergoing palliative chemotherapy at the National Kidney and Transplant Institute, Philippines, was performed using MDASI-F. Results: A total of 114 patients were included with a mean age of 55.5 years. 61% were female, and 39% were male. 81.6% were married, while 14% were single and 4.4% were widowed. Highest educational level attained were college (78.1%), high school (19.3%) and primary school (2.6%). Average Body Mass Index fall on 23 kg/m2. Majority of the patients have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 (54.4%), followed by ECOG 2 (19.3%), ECOG 0 (18.4%), and ECOG 3 (7.9%). The most common cancer site is breast (30.7%), followed by colon (21.9%), and lungs (16.7%), while the remaining 30.7% belong to other cancer sites. Majority of the patients have one metastatic site (68.4%), 22.8% have two, while 8.8% have 3 metastatic sites. Mean duration of illness from the time of diagnosis was 13.67 months. The most severe cancer related symptoms were sleep disturbance (mean 3.48), fatigue (mean 3.36) and pain (mean 3.14). Interestingly, all Filipino metastatic cancer related severity symptoms and interference items belong to the mild severity score (scores of 0-3) using the MDSAI-F. Conclusions: Among Filipino metastatic cancer patients on palliative chemotherapy, cancer-related symptom severity items and interference items were shown to have mild severity scores based on the MDASI-F.
Yolk-shell nanovesicles endow glutathione-responsive concurrent drug release and T1 MRI activation for cancer theranostics
Authors: Dahai Liu, Zijian Zhou, Xinyu Wang, Hongzhang Deng, Lin Sun, Haixin Lin, Fei Kang, Yong Zhang, Zhantong Wang, Weijing Yang, Lang Rao, Kuikun Yang, Guocan Yu, Jianshi Du, Zheyu Shen, Xiaoyuan Chen
Journal: Biomaterials (2020)
LOW INCOME IS LINKED TO A HIGHER RISK OF MORTALITY AND INCIDENT CARDIOVASCULAR (CV) EVENTS IN OLDER ADULTS: A 23-YEAR FOLLOW-UP OF CARDIOVASCULAR HEALTH STUDY (CHS)
Authors: Lowell Safren, Samuel Wopperer, Phillip Hong Lam, Cherinne Arundel, Charles Faselis, Yan Cheng, Prakash Deedwania, Farooq Sheikh, George Howard, Richard Allman, Ali Ahmed
Journal: Journal of the American College of Cardiology (2020)
USE OF MACHINE LEARNING METHODOLOGY TO FIND PREDICTORS OF ALL-CAUSE MORTALITY IN PREVENTION OF EVENTS WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITION (PEACE) TRIAL
Authors: Victoria Xin, Gauri Dandi, Nuha Gani, Zyannah Mallick, Ian Atkinson, Anwar Husain, Adrita Ashraf, Rodica Ciurea, Yuan Gu, Xin Tian, Tejas Patel, Colin Wu, Carlos Cure, Anna Kettermann, George Sopko, Gyorgy Csako, Jerome Fleg, Danielle Jateng, Amit Dey, Victor Crentsil, Keith Burkhart, Eileen Navarro, Frank Pucino, Yves Rosenberg, Ahmed Hasan
Journal: Journal of the American College of Cardiology (2020)
RELATIVE PROGNOSTIC SIGNIFICANCE OF PREVIOUS MYOCARDIAL INFARCTION AND PREVIOUS REVASCULARIZATION IN PATIENTS UNDERGOING SPECT MPI
Authors: Robert J. H Miller, Eyal Klein, Heidi Gransar, Piotr Slomka, John Friedman, Sean W. Hayes, Louise Thomson, Balaji Tamarappoo, Alan Rozanski, Daniel S. Berman
Journal: Journal of the American College of Cardiology (2020)
Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis
Authors: Eun-Jung Lim, Seungmo Kim, Yoonjee Oh, Yongjoon Suh, Neha Kaushik, Ji-Hyun Lee, Hae-June Lee, Min-Jung Kim, Myung-Jin Park, Rae-Kwon Kim, Junghwa Cha, Se Hoon Kim, Jin-Kyoung Shim, Junjeong Choi, Jong Hee Chang, Yong Kil Hong, Yong Min Huh, Pilnam Kim, Seok-Gu Kang, Su-Jae Lee
Journal: Neuro-Oncology (2020)

Mesenchymal stemlike cells (MSLCs) have been detected in many types of cancer including brain tumors and have received attention as stromal cells in the tumor microenvironment. However, the cellular mechanisms underlying their participation in cancer progression remain largely unexplored. The aim of this study was to determine whether MSLCs have a tumorigenic role in brain tumors.To figure out molecular and cellular mechanisms in glioma invasion, we have cultured glioma with MSLCs in a co-culture system.Here, we show that MSLCs in human glioblastoma (GBM) secrete complement component C5a, which is known for its role as a complement factor. MSLC-secreted C5a increases expression of zinc finger E-box-binding homeobox 1 (ZEB1) via activation of p38 mitogen-activated protein kinase (MAPK) in GBM cells, thereby enhancing the invasion of GBM cells into parenchymal brain tissue.Our results reveal a mechanism by which MSLCs undergo crosstalk with GBM cells through the C5a/p38 MAPK/ZEB1 signaling loop and act as a booster in GBM progression.1. MSLCs activate p38 MAPK-ZEB1 signaling in GBM cells through C5a in a paracrine manner, thereby boosting the invasiveness of GBM cells in the tumor microenvironment.2. Neutralizing of C5a could be a potential therapeutic target for GBM by inhibition of mesenchymal phenotype.
Cardiovascular Health Trajectories From Childhood Through Middle Age and Their Association With Subclinical Atherosclerosis
Authors: Norrina B. Allen, Amy E. Krefman, Darwin Labarthe, Philip Greenland, Markus Juonala, Mika Kähönen, Terho Lehtimäki, R. Sue Day, Lydia A. Bazzano, Linda V. Van Horn, Lei Liu, Camilo Fernandez Alonso, Larry S. Webber, Katja Pahkala, Tomi T. Laitinen, Olli T. Raitakari, Donald M. Lloyd-Jones
Journal: JAMA Cardiology (2020)

<h3>Importance</h3> Cross-sectional measures of cardiovascular health (CVH) have been associated with cardiovascular disease in older age, but little is known about longitudinal trajectories in CVH and their association with subclinical atherosclerosis in middle age. <h3>Objectives</h3> To model long-term patterns in CVH starting in childhood and to assess their association with subclinical atherosclerosis in middle age. <h3>Design, Setting, and Participants</h3> This cohort study used data from 5 prospective cardiovascular cohort studies from the United States and Finland from 1973 to 2015. A total of 9388 participants aged 8 to 55 years had at least 3 examinations and were eligible for this study. Statistical analysis was performed from December 1, 2015, to June 1, 2019. <h3>Exposures</h3> Clinical CVH factors (body mass index, total cholesterol level, blood pressure, and glucose level) were classified as ideal, intermediate, or poor, and were summed as a clinical CVH score. Group-based latent class modeling identified trajectories in this score over time. <h3>Main Outcomes and Measures</h3> Carotid intima-media thickness (cIMT) was measured for participants in 3 cohorts, and high cIMT was defined as a value at or above the 90th percentile. The association between CVH trajectory and cIMT was modeled using both linear and logistic regression adjusted for demographics, baseline health behaviors, and baseline (or proximal) CVH score. <h3>Results</h3> Among 9388 participants (5146 [55%] female; 6228 [66%] white; baseline mean [SD] age, 17.5 [7.5] years), 5 distinct trajectory groups were identified: high-late decline (1518 participants [16%]), high-moderate decline (2403 [26%]), high-early decline (3066 [32%]), intermediate-late decline (1475 [16%]), and intermediate-early decline (926 [10%]). The high-late decline group had significantly lower adjusted cIMT vs other trajectory groups (high-late decline: 0.64 mm [95% CI, 0.63-0.65 mm] vs intermediate-early decline: 0.72 mm [95% CI, 0.69-0.75 mm] when adjusted for demographics and baseline smoking, diet, and physical activity;<i>P</i> &lt; .01). The intermediate-early declining group had higher odds of high cIMT (odds ratio, 2.4; 95% CI, 1.3-4.5) compared with the high-late decline group, even after adjustment for baseline or proximal CVH score. <h3>Conclusions and Relevance</h3> In this study, CVH declined from childhood into adulthood. Promoting and preserving ideal CVH from early life onward may be associated with reduced CVD risk later in life.
TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer.
Authors: Seong Joon Park, Seung-mi Kim, Yong Sang Hong, Jae-Lyun Lee, Jeong-Eun Kim, Kyu-Pyo Kim, Dong-Hoon Jin, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Tae Won Kim
Journal: Journal of Clinical Oncology (2013)

3628 Background: Transcription factor AP-2ε, a member of the AP-2 family has extensively studied in many cancers. Recently, it has been suggested that the gene encoding AP-2ε (TFAP2E) is involved in the development of colorectal cancer (CRC) and is also associated with clinical outcomes of the patients with CRCs. Therefore, we have investigated the clinical significance of TFAP2E in CRC patients who underwent curative resections. Methods: A single-institution cohort of 248 patients with curatively resected, stage I/II/III CRCs between March and December, 2004 were included, and the analyses were performed in 193 patients whose tumors were available for TFAP2E methylation status Results: One hundred twelve patients (58%) showed TFAP2E hypermethylation, which was significantly more common in CRCs with distal location, low pathologic T stage (T1/T2) and stage I. After a median follow-up duration of 86.3 months, the patients with TFAP2E hypermethylation had a trend for better survival outcome in terms of relapse-free survival (RFS) and overall survival (OS) (TFAP2E hypermethylation vs. hypomethylation; 5-year RFS rate 90% vs. 80%, p=0.063; 6-year OS rate 88% vs. 80%, p=0.083). Multivariate analysis showed pathologic nodal stage and TFAP2E methylation status were independent prognostic factors affecting both RFS and OS, which also remained significant factors in the subgroup analysis including 154 patients with stage II/III CRCs who had received adjuvant chemotherapy. Conclusions: TFAP2E hypermethylation was associated with better clinical outcome and may be considered as an independent prognostic factor in the patients with curatively resected CRC.
Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection
Authors: Xiaoming Cheng, Takuro Uchida, Yuchen Xia, Regina Umarova, Chun-Jen Liu, Pei-Jer Chen, Anuj Gaggar, Vithika Suri, Marcus M. Mücke, Johannes Vermehren, Stefan Zeuzem, Yuji Teraoka, Mitsutaka Osawa, Hiroshi Aikata, Keiji Tsuji, Nami Mori, Shuhei Hige, Yoshiyasu Karino, Michio Imamura, Kazuaki Chayama, T. Jake Liang
Journal: Journal of Clinical Investigation (2020)

In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied the molecular mechanisms behind this viral interaction. In coinfected cell culture and humanized mice, HBV replication was suppressed by HCV coinfection. In vitro, HBV suppression was attenuated when interferon (IFN) signaling was blocked. In vivo, HBV viremia, after initial suppression by HCV superinfection, rebounded following HCV clearance by DAA treatment that was accompanied by a reduced hepatic IFN response. Using blood samples of coinfected patients, IFN-stimulated gene products including C-X-C motif chemokine 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and alanine aminotransferase (ALT) were identified to have predictive value for HBV reactivation after HCV clearance. Taken together, our data suggest that HBV reactivation is a result of diminished hepatic IFN response following HCV clearance and identify serologic markers that can predict HBV reactivation in DAA-treated HBV-HCV–coinfected persons.
Correction to: Ubrogepant: First Approval
Authors: Lesley J. Scott
Journal: Drugs (2020)

The article Ubrogepant: First Approval, written by Lesley J. Scott, was originally published published Online First without Open Access. After publication online Allergan Sales, LLC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Allergan Sales, LLC. The article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.
PREDICTORS OF NON-USE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH IN HEART FAILURE
Authors: Benedikt Schrage, Alicia Uijl, Davide Stolfo, Lina Benson, Ulf Dahlstrom, Dirk Westermann, Cecilia Linde, Frieder Braunschweig, Gianluigi Savarese, Lars Lund
Journal: Journal of the American College of Cardiology (2020)